Genexis Biotech is at the forefront of a biotechnological revolution, leveraging engineered bacteria to produce animal-free proteins ethically and sustainably. The company’s innovative approach aims to address the global supply chain vulnerabilities highlighted by the Covid-19 pandemic, particularly in the production of foetal bovine serum (FBS) crucial for various biopharmaceutical applications.
By harnessing recombinant technology and precision fermentation, Genexis Biotech has set out to replace traditional methods of protein extraction from animals with a more efficient and ethical alternative. This shift is exemplified by their production of insulin using engineered bacteria instead of extracting it from pig pancreases, highlighting the potential for transforming the biopharmaceutical industry.
The core of Genexis’ technology lies in genetically modifying bacteria to optimize protein production, essentially creating bio-factories within these microscopic organisms. This approach not only ensures a more sustainable source of proteins but also significantly increases production efficiency, leading to a reduction in costs associated with protein manufacturing.
In addition to addressing the FBS shortage, Genexis Biotech is exploring the production of proteins for nutraceuticals and biocosmetics, offering a viable substitute for animal-derived proteins like collagen. The company’s innovative platform technology, currently undergoing patenting processes, extends beyond production to encompass downstream processing, further enhancing the efficiency and versatility of their protein manufacturing.
Operating on a business-to-business model, Genexis Biotech caters to biopharmaceutical companies either directly or through dealer channels. While the company primarily focuses on product sales, it also provides formulation support to clients engaged in biopharmaceutical product development. This flexibility in business models positions Genexis to meet the diverse needs of the biopharmaceutical industry effectively.
The recent partnership with the Gujarat government signifies Genexis Biotech’s commitment to scaling up its production capacity and expanding its product offerings in the coming years. With a focus on smart proteins that address nutritional deficiencies sustainably, the company is poised to make significant contributions to India’s biopharmaceutical landscape and reduce its dependence on imported proteins and growth factors.
In securing seed funding and establishing a state-of-the-art manufacturing facility in Vadodara, Genexis Biotech is laying the foundation for future growth and innovation in the biotech sector. The company’s plans to enhance bioreactor capacity, develop new protein lines, and ensure compliance with Good Manufacturing Practices (GMP) underscore its dedication to excellence and sustainability in protein production.
Key Takeaways:
– Genexis Biotech is revolutionizing protein production by utilizing engineered bacteria for ethical and sustainable manufacturing.
– The company’s focus on animal-free proteins addresses supply chain vulnerabilities and promotes a more sustainable approach to biopharmaceutical production.
– Through innovative genetic engineering and precision fermentation, Genexis Biotech has significantly increased production efficiency and reduced costs associated with protein manufacturing.
– Partnerships with government institutions and strategic investors position Genexis Biotech for expansion and leadership in the development of smart proteins and recombinant enzymes.
Tags: downstream, biotech, cell culture, precision fermentation, bioreactor, nutraceuticals
Read more on thehindubusinessline.com